Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV, a foreign private issuer, for the month of February 2021. The filing, dated February 10, 2021, serves to incorporate by reference a press release (Exhibit 99.1) issued on the same date. The registrant is incorporated in Belgium with its principal executive office in Mechelen. Note: The request metadata references "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as Galapagos NV.
Financial Metrics
The filing text does not provide specific financial data. This document is a procedural submission to incorporate a press release and does not contain revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The filing does not detail material changes in financial performance or operations within the text provided. The primary content is the incorporation of an external press release by reference.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It notes that the press release (Exhibit 99.1) contains quotes from Dr. Walid Abi-Saab and Mr. Onno van de Stolpe, but the content of these quotes is not included in the provided text. The filing confirms the incorporation of this information into various Registration Statements on Forms F-3 and S-8.
Key Facts for Investor Verification
- Verify the content of the attached press release (Exhibit 99.1) for specific operational updates, as the filing text itself contains no substantive business details.
- Confirm the identity of the registrant as Galapagos NV, noting the discrepancy with the "Lakefront Biotherapeutics NV" name in the request metadata.
- Review the referenced Registration Statements (Forms F-3 and S-8) for the full context of the incorporated press release information.
- Check for subsequent filings if the press release contained material financial or clinical data not summarized in this Form 6-K cover page.